3. Target population, drug and dose of the 15 included studies.
| Study | Target population | Drug | Dose |
| Basile 2012 | Bone neoplasm | Dexamethasone | 4 mg/mL |
| Bruera 1985 | Advanced cancer | Methylprednisolone | 32 mg |
| Bruera 2004 | Advanced cancer | Dexamethasone | 20 mg |
| Della 1989 | Advanced cancer | Methylprednisolone | 125 mg |
| Fossa 2001 | Prostate cancer | Prednisone | 20 mg |
| Graham 2006 | Malignant spinal cord compression | Dexamethasone | 16 mg |
| Graham 2006 | Malignant spinal cord compression | Dexamethasone | 96 mg |
| Lauretti 2013 | Advanced cancer | Dexamethasone | 10 mg |
| Lee 2008 | Multiple myeloma | Dexamethasone | 40 mg |
| Mercadante 2007 | Adjuvant drug in advanced cancer patients | Dexamethasone | 8 mg |
| Paulsen 2014 | Advanced cancer | Methylprednisolone | 16 mg |
| Popiela 1989 | Advanced cancer | Methylprednisolone | 125 mg |
| Teshima 1996 | Bone metastases | Methylprednisolone | 500 mg |
| Twycross 1985 | Breast or bronchus cancer | Prednisolone | 15 mg |
| Vecht 1989 | Advanced cancer | Dexamethasone | 10 mg |
| Vecht 1989 | Advanced cancer | Dexamethasone | 100 mg |
| Yennurajalingam 2013 | Advanced cancer | Dexamethasone | 8 mg |